239 related articles for article (PubMed ID: 5081590)
21. Antigenic changes associated with resistance to methotrexate and 6-mercaptopurine in L1210 ascites lymphoma.
Calman NS; Eng B; Slater LM; Wallerstein H
J Natl Cancer Inst; 1974 Mar; 52(3):997-8. PubMed ID: 4826575
[No Abstract] [Full Text] [Related]
22. [Effect of combination chemotherapy of nitrosourea MCNU with various anti-tumor agents].
Ninomiya K; Sekido S; Araki T
Gan To Kagaku Ryoho; 1984 Jun; 11(6):1315-23. PubMed ID: 6428326
[TBL] [Abstract][Full Text] [Related]
23. Letter: Proposed new derivative of cytosine arabinoside (NSC-63878) to circumvent resistance.
Cysyk RL
Cancer Chemother Rep; 1974; 58(3):298-9. PubMed ID: 4842665
[No Abstract] [Full Text] [Related]
24. Sequential administration of two oncostatic drugs: study of modalities for pharmacodynamic potentiation.
Pouillart R; Huong TH; Brugerie E; Lheritier J
Biomedicine; 1974 Dec; 21(12):471-9. PubMed ID: 4462870
[No Abstract] [Full Text] [Related]
25. Effect of combined therapy with cytosine arabinoside (NSC-63878) and l,3-bis-(2-chloroethyl)-1-nitrosourea (NSC-409962) on sarcoma 180 and L1210 in vivo.
Mizuno NS; Humphrey EW
Cancer Chemother Rep; 1969 Sep; 53(4):215-21. PubMed ID: 5384462
[No Abstract] [Full Text] [Related]
26. Single versus combination chemotherapy of L1210 leukemia.
Koza I; Balázová E; Ujházy V
Neoplasma; 1980; 27(6):691-6. PubMed ID: 7254424
[TBL] [Abstract][Full Text] [Related]
27. Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388.
Góra-Tybor J; Robak T
Acta Haematol Pol; 1993; 24(2):177-82. PubMed ID: 8103959
[TBL] [Abstract][Full Text] [Related]
28. Deveopment of resistance to combinations of six antimetabolites in mice with L1210 leukemia.
Schmid FA; Hutchison DJ; Otter GM; Stock CC
Cancer Treat Rep; 1976 Jan; 60(1):23-7. PubMed ID: 1000516
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. IX.
Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
Cancer Chemother Rep 2; 1971 Apr; 2(1):65-133. PubMed ID: 5565539
[No Abstract] [Full Text] [Related]
30. [Transplantability, development and methotrexate sensitivity of mouse leukemia L1210 resistant to olivomycin].
Prokhorova EV
Antibiotiki; 1978 Jun; 23(6):553-7. PubMed ID: 677843
[TBL] [Abstract][Full Text] [Related]
31. [Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside].
Bukhman VM; Lichinitser MR; Svet-Moldavskiĭ GIa; Mkheidze DM
Biull Eksp Biol Med; 1978 Mar; 85(3):340-3. PubMed ID: 276385
[TBL] [Abstract][Full Text] [Related]
32. Immunosuppressive activity of methotrexate and arabinosyl cytosine in mice bearing L1210 leukaemia.
Baldini L; Brambilla G; Cavanna M; Parodi S
Br J Pharmacol; 1968 Nov; 34(3):674P-676P. PubMed ID: 5726804
[No Abstract] [Full Text] [Related]
33. Combination chemotherapy with cyclophosphamide (NSC-26271), cytosine arabinoside (NSC-63878), and methotrexate (NSC-740) in advanced solid tumors.
Odujinrin OO; DeConti RC; Bertino JR
Cancer Chemother Rep; 1975; 59(6):1091-6. PubMed ID: 769948
[TBL] [Abstract][Full Text] [Related]
34. Basis of observed resistance of L1210 leukemia in mice: methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mercaptopurine, 5-fluorouracil, and 1-beta-D-arabinofuranosylcytosine administered in different combinations.
Kim K; Blechman WJ; Riddle VG; Pardee AB
Cancer Res; 1981 Nov; 41(11 Pt 1):4529-34. PubMed ID: 7198006
[TBL] [Abstract][Full Text] [Related]
35. [Studies on the mechanisms of resistance to methotrexate--with special emphasis on the change of nucleotide pools].
Nobori T; Shimizu N; Ohkubo T; Kawasaki H; Sako T; Komada M; Hirota H; Kamiya H; Sakurai M
Nihon Ketsueki Gakkai Zasshi; 1986 May; 49(3):661-9. PubMed ID: 3766065
[No Abstract] [Full Text] [Related]
36. Chronochemotherapy: L 1210 leukemia and beyond.
Halberg F; Nelson W; Cornélissen G; Haus E; Scheving LE; Good RA
Chronobiologia; 1979; 6(3):203-11. PubMed ID: 520097
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic performance of carminomycin-cyclophosphamide against L1210 leukemia.
Avery TL; Cruze PG
Cancer Res; 1978 Sep; 38(9):2892-5. PubMed ID: 679196
[No Abstract] [Full Text] [Related]
38. Effect of reserpine (NSC-59272)-induced hypothermia on lifespan in mouse L1210 leukemia.
Fondy TP; Karker KL; Calcagnino C; Emlich CA
Cancer Chemother Rep; 1974; 58(3):317-24. PubMed ID: 4841715
[No Abstract] [Full Text] [Related]
39. Biochemical and pharmacologic study of therapeutic synergism with cyclophosphamide plus methotrexate in murine L1210 leukemia.
Klubes P; Cerna I
Cancer Treat Rep; 1981; 65(1-2):107-14. PubMed ID: 7226161
[TBL] [Abstract][Full Text] [Related]
40. Selective chemotherapy for advanced murine L 1210 leukemia by combination of 2' deoxycytidine and lethal doses of cytosine-arabinoside.
Buchman VM; Svet-Maoldavsky GJ; Lichinitser MR; Mkheidze DM
Biomedicine; 1977 Jul; 27(5):179-80. PubMed ID: 922116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
